AbbVie Looks To White House For Relief From US FDA Naming Guidance

Company says requirement that distinguishable suffixes be added to existing biologics creates the kind of economic burden targeted in President Trump’s executive order aimed at undoing the Affordable Care Act, which also established the biosimilar pathway.